Physician profile
Robert S Cady
NPI 1174529564
$5,761.51
in general payments reported to CMS, 2019-2025
14 companies · $565 in 2025
The $565 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $251 · 2021: $1,000 · 2022: $1,495 · 2023: $926 · 2024: $796 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,857.86 | 2019-2025 | Idose, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| US Retina LLC | $1,560.35 | 2019-2022 | |
| Alcon Vision LLC | $759.93 | 2019-2025 | Lensx, Clareon, Hydrus Microstent |
| Abbvie INC. | $755.61 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| New World Medical,INC. | $146.28 | 2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Bausch & Lomb Americas INC. | $136.01 | 2022-2024 | Vyzulta, Miebo |
| Aerie Pharmaceuticals, INC. | $120.68 | 2019-2021 | |
| Allergan, INC. | $118.33 | 2019-2022 | |
| Sight Sciences, INC. | $88.90 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $67.27 | 2024-2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $66.69 | 2025 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $42.10 | 2023 | |
| Genentech USA, INC. | $21.72 | 2025 | Susvimo |
| Thea Pharma INC. | $19.78 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,631.01 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.